ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Pooled it
- ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counselling, surveillance, quality of life, and clinical management.European journal of human genetics : EJHG · 2024Guideline
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer.The New England journal of medicine · 2026Trial
- Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial.Nature communications · 2025Trial
- SLAMF6 Enhances the Efficacy of Anti-PD-L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis.Cancer science · 2026Article
- Universal off-the-shelf TGF-Acta pharmaceutica Sinica. B · 2026Article
- Report from the 27th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Calgary, Alberta, 26-27 September 2025: Advances in Colon and Rectal Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Review
- The impact of international care networks on the clinical management of constitutional mismatch repair deficiency (CMMRD): a review of recent developments.Familial cancer · 2026Review
- Bowel obstruction in mismatch repair-deficient colorectal cancer with excellent response to immunotherapy: a case series.Annals of coloproctology · 2026Article
- Impact of mucinous histology on the efficacy of neoadjuvant immunotherapy in localized mismatch repair-deficient colorectal cancer.BMC cancer · 2026Article
- Clinicopathological characteristics and stage-adjusted outcomes of sporadic pMMR/MSS early-onset colorectal cancer.BMC gastroenterology · 2026Article
- Prognostic Impact of Histologic Subtypes in Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer: A Single-Center Retrospective Study of 1127 Stage 0-IV Patients.Annals of gastroenterological surgery · 2026Article
- PRELID1 and VDAC3 Coordinate a Senescence-Like State in Germinal Center B Cells to Promote IL-7-Driven Antitumor Immunity in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancements and innovations in the molecular mechanisms and treatment of colorectal cancer.Discover oncology · 2026Review
- Multifunctional copper-based nanoparticles potentiate colorectal cancer immunotherapy via synergistic metabolic remodeling and cGAS-STING pathway activation.Journal of nanobiotechnology · 2026Article
- Recognition of immunogenomic signature and prognostic value of the subtype of epithelial-mesenchymal transition in breast cancer.Biochemistry and biophysics reports · 2026Article
- The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026Article
- Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study.Journal of clinical medicine · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by hypermutation leading to abundant neoantigens that activate an antitumor immune response in the tumor microenvironment. Immune checkpoint inhibitors (ICIs) have transformed the treatment of this subset of CRC and other solid tumors with dMMR, by producing frequent and durable responses that extend patient survival. Recently, the anti-programmed death-1 (PD-1) antibody pembrolizumab was shown to produce significantly longer progression-free survival with fewer adverse events compared with chemotherapy as first-line treatment of metastatic CRC (mCRC) with dMMR. Accordingly, single-agent pembrolizumab represents a new standard of care for dMMR mCRCs including patients with Lynch syndrome and the more common sporadic cases. Furthermore, data indicate that the combination of PD-1 and cytotoxic T-cell lymphocyte-4 inhibitors was more effective than single-agent PD-1 inhibition in patients with dMMR mCRCs, suggesting nonredundant mechanisms of action. Although the benefit of ICIs is currently limited to metastatic disease, studies evaluating ICIs as neoadjuvant and adjuvant therapy in earlier-stage dMMR CRC are ongoing. Despite success of ICIs in the treatment of metastatic dMMR cancers, an appreciable proportion of these tumors demonstrate intrinsic or acquired resistance, and biomarkers to identify these patients are needed. Advances in the understanding of immunotherapy resistance mechanisms hold promise for both biomarker identification and development of novel strategies to circumvent treatment resistance. In this review, we present a comprehensive overview of the evidence for the role of immunotherapy in the treatment of dMMR CRC, discuss resistance mechanisms, and outline potential strategies to circumvent primary and secondary resistance with the goal of broadening the benefit of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.